Fig. 2

CLSM observation for internalization process: (A) treated with LMOFePt, pLMOFePt, pLMOFePt + amiloride, and pLMOFePt + 4℃ at the dosage of 40 μg/mL; (B) treated with pLMOFePt for different time at the dosage of 40 μg/mL; (C) treated with different concentrations of pLMOFePt for 4 h. ICP-MS quantitative analysis for internalization process: (D) treated with LMOFePt, pLMOFePt, pLMOFePt + amiloride, and pLMOFePt + 4℃ at the dosage of 40 μg/mL; (E) treated with different concentrations of pLMOFePt and pLMOFePt for different time at the dosage of 40 μg/mL (n=3, mean±SEM, *Means p < 0.05, **Means p < 0.01, ***Means p < 0.001). (F) Fluorescent intensity and (G) Fluorescent images of 4T1 tumor-bearing mice after injection of Cy7-labeled LMOFePt or Cy7-labeled pLMOFePt at the dosage of 10 mg/kg. (H) Fluorescent intensity of major organs and tumors in 4T1 tumor-bearing mice after injection Cy7-labeled LMOFePt or pLMOFePt at the dosage of 10 mg/kg for 48 h